Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma, Kaposi 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Head and Neck Neoplasms 1HIV Infections 1Carcinoma, Renal Cell 1Carcinoma, Adenoid Cystic 1AIDS-related Kaposi sarcoma 1AIDS-Related Opportunistic Infections 1

Interventions

Paclitaxel 134Carboplatin 129Bevacizumab 86Gemcitabine 45pembrolizumab 37olaparib 33Cisplatin 30liposomal doxorubicin 29Docetaxel 29Cyclophosphamide 29Topotecan 28niraparib 27Taxes 20Etoposide 18Filgrastim 16Doxorubicin 16Immunoglobulin G 15Disulfides 15apatinib 12Letrozole 12Albumin-Bound Paclitaxel 12Drug Therapy 11fluzoparib 10fludarabine 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 10durvalumab 9Nivolumab 9pazopanib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasms × Nelfinavir × Clear all
NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

Medical University of South Carolina

Phase 2 Recruiting
38 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡